Investing.com -- GSK Plc's CEO Emma Walmsley has expressed intentions to engage in more business deals, as the British pharmaceutical company intensifies its focus on cancer treatments. This comes after GSK made several agreements in 2024, including a deal with cancer biotech firm IDRx, Inc., worth up to $1.15 billion, which was announced on Monday.
The acquisition of IDRx is aimed at procuring an experimental drug for the treatment of gastrointestinal stromal tumors. If the drug proves successful, it will be the first significant advancement in nearly two decades, according to the companies.
Walmsley stated that GSK's renewed focus on oncology is a strategic move to expand its specialty medicines portfolio. The company has plans to advance the IDRx drug to late-stage trials within the year.
In response to questions concerning the vaccine skepticism of Robert F. Kennedy Jr., President-elect Donald Trump's nominee for the Department of Health and Human Services, Walmsley stated that GSK had a fruitful collaboration with the first Trump administration. Looking ahead to 2025, she expressed optimism and ambition.
Walmsley also addressed concerns about potential tariff threats from Trump's administration. She pointed out that historically, tariffs have not been applied to healthcare. She emphasized GSK's commitment to its operations in America, but also noted the company's global presence and its priority to deliver its products to those in need.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.